Paclitaxel trevatide
Paclitaxel trevatide (development codes NG1005 and GRN1005) is an experimental chemotherapy drug that is under development by Angiochem Inc, a Canadian biotech company. Phase II clinical trials have completed for several indications, and the company is preparing for phase III trials.
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
Paclitaxel trevatide
Paclitaxel trevatide (development codes NG1005 and GRN1005) is an experimental chemotherapy drug that is under development by Angiochem Inc, a Canadian biotech company. Phase II clinical trials have completed for several indications, and the company is preparing for phase III trials.
has abstract
Paclitaxel trevatide (developm ...... ce and rats with glioblastoma.
@en
CAS number
1075214-55-9
DrugBank
FDA UNII code
8P77G99D3P
Link from a Wikipage to an external page
Wikipage page ID
20,426,260
page length (characters) of wiki page
Wikipage revision ID
1,020,026,908
Link from a Wikipage to another Wikipage
CAS number
ChemSpiderID
35,003,422
DrugBank
DB06171
@en
legal status
Investigational
@en
SMILES
CC1=C2[C@@H]OCC
@en
StdInChIKey
GBVKRUOMSUTVPW-KARLVTCBSA-N
@en
synonyms
NG1005; GRN1005
@en
wikiPageUsesTemplate
comment
Paclitaxel trevatide (developm ...... reparing for phase III trials.
@en
label
Paclitaxel trevatide
@en